Article in Laboratory investigation; a journal of technical methods and pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Kurt A ZimmermanDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Cheng J SongDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ernald J G AloriaDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Zhang LiDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Juling ZhouDepartment of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Sarah J BlandDepartment of Internal Medicine, Division of Nephrology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Alex YashchenkoDepartment of Internal Medicine, Division of Nephrology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.ORCID 0000-0003-2558-7752
David K CrossmanDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-0981-169X
Michal MrugDepartment of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bradley K YoderDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA. byoder@uab.edu.ORCID 0000-0002-0247-1944
University of Alabama at Birmingham · USUniversity of Oklahoma Health Sciences Center · US
Funding
UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Vascular-macrophage crosstalk in GBM immunosuppressionP20GM134973 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Sree Deepthi Muthukrishnan · 2020 to 2026
$17.6M
UAB Recessive PKD Research and Translational Core CenterP30DK074038 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YODER, BRADLEY K. · 2005 to 2019
$16.6M
IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
Research BaseP30DK090868 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI WATNICK, TERRY J · 2010 to 2019
$11.1M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
Injury Response Mediated Pathogenesis in Renal CiliopathiesR01DK115752 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Bradley K. Yoder · 2018 to 2026
$4.0M
Mechanisms of C3 effects in ARPKD pathogenesisR01DK097423 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MRUG, MICHAL · 2013 to 2017
$1.6M
Investigating CD4 T regulatory cells during rapid cystogenesisK01DK119375 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZIMMERMAN, KURT A · 2020 to 2023
$608k
Pathobiology of Complement C3 effects in ADPKDI01BX002298 · VA · BIRMINGHAM VA MEDICAL CENTER · PI MRUG, MICHAL · 2014 to 2017
–
Role of NOD2 in Inflammatory Arthritis and Innate ImmunityI01BX000229 · VA · PORTLAND VA MEDICAL CENTER · PI DAVEY, MICHAEL PATRICK · 2009 to 2012
Hepatorenal fibrocystic disease (HRFCD) is a genetically inherited disorder related to primary cilia dysfunction in which patients display varying levels of fibrosis, bile duct expansion, and inflammation. In mouse models of HRFCD, the phenotype is greatly impacted by the genetic background in which the mutation is placed. Macrophages are a common factor associated with progression of HRFCD and are also strongly influenced by the genetic background. These data led us to hypothesize that macrophage subtypes that change in relation to the genetic background are responsible for the variable phenotypic outcomes in HRFCD. To test this hypothesis, we utilized a mouse model of HRFCD (Ift88
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Early infiltrating macrophage subtype correlates with late-stage phenotypic outcome in a mouse model of hepatorenal fibrocystic disease. · full record | OpenQuestion